Free Trial

Creo Medical Group (CREO) Competitors

Creo Medical Group logo
GBX 10 0.00 (0.00%)
As of 11:50 AM Eastern

CREO vs. EKF, SPEC, IUG, BVC, and NCYT

Should you buy Creo Medical Group stock or one of its competitors? Creo Medical Group's main competitors and comparable companies include EKF Diagnostics (EKF), INSPECS Group (SPEC), Intelligent Ultrasound Group (IUG), BATM Advanced Communications (BVC), and Novacyt (NCYT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment & supplies" industry.

How does Creo Medical Group compare to EKF Diagnostics?

EKF Diagnostics (LON:EKF) and Creo Medical Group (LON:CREO) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, dividends, profitability, valuation, earnings, risk and institutional ownership.

EKF Diagnostics presently has a consensus price target of GBX 35, indicating a potential upside of 44.03%. Creo Medical Group has a consensus price target of GBX 40, indicating a potential upside of 295.06%. Given Creo Medical Group's higher possible upside, analysts clearly believe Creo Medical Group is more favorable than EKF Diagnostics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
EKF Diagnostics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Creo Medical Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

EKF Diagnostics has higher revenue and earnings than Creo Medical Group. Creo Medical Group is trading at a lower price-to-earnings ratio than EKF Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
EKF Diagnostics£51.35M2.03£4.68M£0.5841.90
Creo Medical Group£7M6.50-£25.04M-£5.00N/A

EKF Diagnostics has a beta of 0.503, indicating that its share price is 50% less volatile than the broader market. Comparatively, Creo Medical Group has a beta of 1.563854, indicating that its share price is 56% more volatile than the broader market.

21.5% of EKF Diagnostics shares are held by institutional investors. Comparatively, 44.0% of Creo Medical Group shares are held by institutional investors. 40.2% of EKF Diagnostics shares are held by company insiders. Comparatively, 7.6% of Creo Medical Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Creo Medical Group had 1 more articles in the media than EKF Diagnostics. MarketBeat recorded 1 mentions for Creo Medical Group and 0 mentions for EKF Diagnostics. EKF Diagnostics' average media sentiment score of 0.00 equaled Creo Medical Group'saverage media sentiment score.

Company Overall Sentiment
EKF Diagnostics Neutral
Creo Medical Group Neutral

EKF Diagnostics has a net margin of 4.86% compared to Creo Medical Group's net margin of -268.57%. EKF Diagnostics' return on equity of 3.58% beat Creo Medical Group's return on equity.

Company Net Margins Return on Equity Return on Assets
EKF Diagnostics4.86% 3.58% 5.27%
Creo Medical Group -268.57%-38.29%-20.09%

Summary

EKF Diagnostics beats Creo Medical Group on 10 of the 15 factors compared between the two stocks.

How does Creo Medical Group compare to INSPECS Group?

INSPECS Group (LON:SPEC) and Creo Medical Group (LON:CREO) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, institutional ownership, valuation, risk, dividends and media sentiment.

INSPECS Group has a beta of 1.603, suggesting that its share price is 60% more volatile than the broader market. Comparatively, Creo Medical Group has a beta of 1.563854, suggesting that its share price is 56% more volatile than the broader market.

In the previous week, Creo Medical Group had 1 more articles in the media than INSPECS Group. MarketBeat recorded 1 mentions for Creo Medical Group and 0 mentions for INSPECS Group. INSPECS Group's average media sentiment score of 0.00 equaled Creo Medical Group'saverage media sentiment score.

Company Overall Sentiment
INSPECS Group Neutral
Creo Medical Group Neutral

INSPECS Group has a net margin of -0.52% compared to Creo Medical Group's net margin of -268.57%. INSPECS Group's return on equity of -1.19% beat Creo Medical Group's return on equity.

Company Net Margins Return on Equity Return on Assets
INSPECS Group-0.52% -1.19% 0.45%
Creo Medical Group -268.57%-38.29%-20.09%

INSPECS Group has higher revenue and earnings than Creo Medical Group. INSPECS Group is trading at a lower price-to-earnings ratio than Creo Medical Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
INSPECS Group£193.23M0.49-£4.11M-£5.34N/A
Creo Medical Group£7M6.50-£25.04M-£5.00N/A

0.7% of INSPECS Group shares are held by institutional investors. Comparatively, 44.0% of Creo Medical Group shares are held by institutional investors. 19.6% of INSPECS Group shares are held by company insiders. Comparatively, 7.6% of Creo Medical Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

INSPECS Group beats Creo Medical Group on 7 of the 12 factors compared between the two stocks.

How does Creo Medical Group compare to Intelligent Ultrasound Group?

Intelligent Ultrasound Group (LON:IUG) and Creo Medical Group (LON:CREO) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, media sentiment, earnings and dividends.

Intelligent Ultrasound Group has higher earnings, but lower revenue than Creo Medical Group. Creo Medical Group is trading at a lower price-to-earnings ratio than Intelligent Ultrasound Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Intelligent Ultrasound Group£6.57M0.00-£2.27M-£0.68N/A
Creo Medical Group£7M6.50-£25.04M-£5.00N/A

In the previous week, Creo Medical Group had 1 more articles in the media than Intelligent Ultrasound Group. MarketBeat recorded 1 mentions for Creo Medical Group and 0 mentions for Intelligent Ultrasound Group. Intelligent Ultrasound Group's average media sentiment score of 0.00 equaled Creo Medical Group'saverage media sentiment score.

Company Overall Sentiment
Intelligent Ultrasound Group Neutral
Creo Medical Group Neutral

Intelligent Ultrasound Group has a beta of 0.38, indicating that its share price is 62% less volatile than the broader market. Comparatively, Creo Medical Group has a beta of 1.563854, indicating that its share price is 56% more volatile than the broader market.

Intelligent Ultrasound Group has a net margin of -23.11% compared to Creo Medical Group's net margin of -268.57%. Intelligent Ultrasound Group's return on equity of -23.58% beat Creo Medical Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Intelligent Ultrasound Group-23.11% -23.58% -13.51%
Creo Medical Group -268.57%-38.29%-20.09%

75.5% of Intelligent Ultrasound Group shares are held by institutional investors. Comparatively, 44.0% of Creo Medical Group shares are held by institutional investors. 12.8% of Intelligent Ultrasound Group shares are held by insiders. Comparatively, 7.6% of Creo Medical Group shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Intelligent Ultrasound Group beats Creo Medical Group on 7 of the 11 factors compared between the two stocks.

How does Creo Medical Group compare to BATM Advanced Communications?

BATM Advanced Communications (LON:BVC) and Creo Medical Group (LON:CREO) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and dividends.

BATM Advanced Communications has a net margin of -15.91% compared to Creo Medical Group's net margin of -268.57%. BATM Advanced Communications' return on equity of -25.90% beat Creo Medical Group's return on equity.

Company Net Margins Return on Equity Return on Assets
BATM Advanced Communications-15.91% -25.90% 0.58%
Creo Medical Group -268.57%-38.29%-20.09%

BATM Advanced Communications has higher revenue and earnings than Creo Medical Group. BATM Advanced Communications is trading at a lower price-to-earnings ratio than Creo Medical Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BATM Advanced Communications£104.57M0.36-£278.26K-£3.94N/A
Creo Medical Group£7M6.50-£25.04M-£5.00N/A

14.3% of BATM Advanced Communications shares are owned by institutional investors. Comparatively, 44.0% of Creo Medical Group shares are owned by institutional investors. 31.0% of BATM Advanced Communications shares are owned by company insiders. Comparatively, 7.6% of Creo Medical Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

BATM Advanced Communications has a beta of 0.754, suggesting that its stock price is 25% less volatile than the broader market. Comparatively, Creo Medical Group has a beta of 1.563854, suggesting that its stock price is 56% more volatile than the broader market.

In the previous week, BATM Advanced Communications had 2 more articles in the media than Creo Medical Group. MarketBeat recorded 3 mentions for BATM Advanced Communications and 1 mentions for Creo Medical Group. BATM Advanced Communications' average media sentiment score of 0.73 beat Creo Medical Group's score of 0.00 indicating that BATM Advanced Communications is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BATM Advanced Communications
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Creo Medical Group
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

BATM Advanced Communications beats Creo Medical Group on 9 of the 13 factors compared between the two stocks.

How does Creo Medical Group compare to Novacyt?

Novacyt (LON:NCYT) and Creo Medical Group (LON:CREO) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, earnings, risk, valuation, institutional ownership and profitability.

10.7% of Novacyt shares are held by institutional investors. Comparatively, 44.0% of Creo Medical Group shares are held by institutional investors. 0.4% of Novacyt shares are held by insiders. Comparatively, 7.6% of Creo Medical Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Creo Medical Group has lower revenue, but higher earnings than Novacyt. Creo Medical Group is trading at a lower price-to-earnings ratio than Novacyt, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novacyt£21.79M1.22-£36.80M-£31.00N/A
Creo Medical Group£7M6.50-£25.04M-£5.00N/A

Novacyt has a net margin of -102.66% compared to Creo Medical Group's net margin of -268.57%. Creo Medical Group's return on equity of -38.29% beat Novacyt's return on equity.

Company Net Margins Return on Equity Return on Assets
Novacyt-102.66% -159.13% -27.98%
Creo Medical Group -268.57%-38.29%-20.09%

Novacyt has a beta of 1.112, meaning that its stock price is 11% more volatile than the broader market. Comparatively, Creo Medical Group has a beta of 1.563854, meaning that its stock price is 56% more volatile than the broader market.

In the previous week, Novacyt and Novacyt both had 1 articles in the media. Novacyt's average media sentiment score of 1.30 beat Creo Medical Group's score of 0.00 indicating that Novacyt is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Novacyt
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Creo Medical Group
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Creo Medical Group beats Novacyt on 8 of the 12 factors compared between the two stocks.

Get Creo Medical Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for CREO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CREO vs. The Competition

MetricCreo Medical GroupHealthcare Equipment & Supplies IndustryHealthcare SectorLON Exchange
Market Cap£44.91M£5.99B£7.86B£2.84B
Dividend YieldN/A1.69%2.47%5.11%
P/E Ratio-2.0039.1434.4123.37
Price / Sales6.424.908.095.05
Price / Cash2.4324.1821.0220.23
Price / Book0.764.964.782.51
Net Income-£25.04M£143.12M£3.52B£5.88B
7 Day Performance-5.30%-4.60%-4.98%-0.01%
1 Month Performance-4.31%-2.38%-3.20%-2.14%
1 Year Performance-5.03%-0.13%-0.27%7.21%

Creo Medical Group Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CREO
Creo Medical Group
N/AGBX 10
flat
GBX 40
+300.0%
-5.0%£44.91M£7MN/A279
EKF
EKF Diagnostics
N/AGBX 24
-1.6%
GBX 35
+45.8%
-7.0%£102.71M£51.35M41.38356
SPEC
INSPECS Group
N/AGBX 87.50
flat
N/A+19.9%£95.53M£193.23MN/A1,673
IUG
Intelligent Ultrasound Group
N/AN/AN/AN/A£42.76M£6.57MN/A65
BVC
BATM Advanced Communications
N/AGBX 11.15
-0.9%
N/A-28.1%£37.90M£104.57MN/A980

Related Companies and Tools


This page (LON:CREO) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners